Kirsten C Morley Selected Research

Baclofen

1/2022	Sex as a Potential Moderator for Baclofen Response in the Treatment of Alcohol Dependence.
1/2022	GABAB Receptors and Alcohol Use Disorders: Clinical Studies.
5/2021	Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals.
1/2021	High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals: Preliminary findings from a pharmaco-fMRI study.
1/2020	Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study.
1/2020	Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals.
5/2019	Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.
1/2019	A Review of Baclofen Overdoses in Australia: Calls to a Poisons Information Centre and a Case Series.
12/2018	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.
12/2018	Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kirsten C Morley Research Topics

Disease

22	Alcoholism (Alcohol Abuse) 01/2022 - 10/2006
4	Alcohol-Related Disorders 01/2022 - 01/2020
4	Liver Diseases (Liver Disease) 01/2022 - 01/2018
3	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2020 - 01/2018
3	Hyperthermia 06/2004 - 06/2002
2	Mental Disorders (Mental Disorder) 10/2021 - 10/2021
2	Hypothermia 06/2004 - 08/2003
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2022
1	Cognitive Dysfunction 01/2020
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2019
1	Disorders of Excessive Somnolence (Hypersomnia) 01/2019
1	Substance-Related Disorders (Drug Abuse) 04/2018
1	Marijuana Abuse (Cannabis Abuse) 01/2012
1	Serotonin Syndrome (Syndrome, Serotonin) 06/2005
1	Drug Fever 08/2003

Drug/Important Bio-Agent (IBA)

13	Baclofen FDA LinkGeneric 01/2022 - 01/2018
6	Pharmaceutical PreparationsIBA 10/2021 - 08/2003
4	Acamprosate (Campral)FDA Link 10/2021 - 10/2006
4	Naltrexone (ReVia)FDA LinkGeneric 08/2018 - 10/2006
4	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 06/2005 - 06/2002
3	Serotonin (5 Hydroxytryptamine)IBA 06/2005 - 08/2003
2	Opioid Analgesics (Opioids)IBA 10/2021 - 01/2019
2	gamma-Aminobutyric Acid (GABA)IBA 01/2021 - 01/2020
1	Varenicline (Chantix)FDA Link 10/2021
1	GABA-B ReceptorsIBA 01/2021
1	CytokinesIBA 10/2020
1	Protons (Proton)IBA 01/2020
1	GABA-B Receptor AgonistsIBA 01/2020
1	N-acetylaspartate (N-acetyl aspartate)IBA 01/2020
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2020
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2019
1	Methadone (Dolophine)FDA LinkGeneric 01/2019
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 08/2018
1	Topiramate (Topamax)FDA LinkGeneric 08/2018
1	Cysteine (L-Cysteine)FDA Link 01/2018
1	Hypnotics and Sedatives (Sedatives)IBA 01/2012
1	Antipsychotic Agents (Antipsychotics)IBA 01/2012
1	periciazineIBA 01/2012
1	KetanserinIBA 06/2005
1	3- (3- (dimethylamino)propyl)- 4- hydroxy- N- (4- (4- pyridinyl)phenyl)benzamideIBA 06/2005
1	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 06/2005
1	CannabinoidsIBA 06/2004
1	RimonabantIBA 06/2004

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
3	Secondary Prevention 01/2022 - 10/2006
1	Induced Hyperthermia (Thermotherapy) 06/2004